Jifeng Yu

发表

Research progress on dendritic cell vaccines in cancer immunotherapy

Weijie Cao, Jifeng Yu, Hao Sun, 2022, Experimental Hematology & Oncology.

Targeting CD47 for cancer immunotherapy

Jifeng Yu, Hao Sun, Yongping Song, 2021, Journal of Hematology & Oncology.

MiR-150-5p regulate T cell activation in severe aplastic anemia by targeting Bach2

F. Wang, Yingmei Li, Jifeng Yu, 2021, Cell and Tissue Research.

SPOP accelerates acute myeloid leukemia initiation and development through miR-183-mediated METAP2 inhibition

Yingmei Li, Jifeng Yu, Zhongxing Jiang, 2020 .

Claudin18.2 is a novel molecular biomarker for tumor-targeted immunotherapy

Weijie Cao, Yingmei Li, Jifeng Yu, 2022, Biomarker research.

Intestinal microbiota score could predict survival following allogeneic hematopoietic stem cell transplantation

W. Li, Jifeng Yu, Zhongxing Jiang, 2022, Annals of Hematology.

Frontiers in the COVID-19 vaccines development

Jifeng Yu, Jiancheng Guo, Ehtisham ul Haq, 2020, Experimental Hematology & Oncology.

Post-remission measurable residual disease directs treatment choice and improves outcomes for patients with intermediate-risk acute myeloid leukemia in CR1

Jifeng Yu, Zhongxing Jiang, Hui-Qing Sun, 2022, International Journal of Hematology.

Crystal Structure of Human CD47 in Complex with Engineered SIRPα.D1(N80A)

Yongping Song, D. Liu, Jifeng Yu, 2022, Molecules.

Significance of bone marrow fibrosis in acute myeloid leukemia for survival in the real-world

Fang Wang, Jifeng Yu, Zhongxing Jiang, 2022, Frontiers in Oncology.

Post-remission measurable residual disease directs treatment choice and improves outcomes for patients with intermediate-risk acute myeloid leukemia in CR1

Jifeng Yu, Zhongxing Jiang, Hui-Qing Sun, 2022, International Journal of Hematology.

SPOP promotes acute myeloid leukemia initiation and development through miR-183-mediated METAP2 inhibition

Yingmei Li, Jifeng Yu, Zhongxing Jiang, 2020, Molecular Therapy - Nucleic Acids.

Targeting toll-like receptor 7/8 for immunotherapy: recent advances and prospectives

P. Zhang, Yongping Song, Yingmei Li, 2022, Biomarker Research.

CLEC12A plays an important role in immunomodulatory function and prognostic significance of patients with acute myeloid leukemia

Weijie Cao, Jifeng Yu, Zhongxing Jiang, 2022, Leukemia & lymphoma.

Prognostic prediction of novel risk scores (AML-DRG and AML-HCT-CR) in acute myeloid leukemia patients with allogeneic hematopoietic stem cell transplantation

Weijie Cao, Jifeng Yu, Zhongxing Jiang, 2021, Scientific Reports.

Applications of gut microbiota in patients with hematopoietic stem-cell transplantation

Weijie Cao, Jifeng Yu, Hao Sun, 2020, Experimental Hematology & Oncology.

Advances in targeted therapy for acute myeloid leukemia

Yingmei Li, Jifeng Yu, Hao Sun, 2020, Biomarker Research.

Advances in targeted therapy for acute myeloid leukemia

Jifeng Yu, Hao Sun, Yongping Song, 2020, Biomarker Research.

Differential U2AF1 mutation sites, burden and co-mutation genes can predict prognosis in patients with myelodysplastic syndrome

Jifeng Yu, Zhongxing Jiang, Zhenkun Dong, 2020, Scientific Reports.

How to select IgG subclasses in developing anti-tumor therapeutic antibodies

Jifeng Yu, Yongping Song, Wenzhi Tian, 2020, Journal of Hematology & Oncology.

Claudin18.2 is a novel molecular biomarker for tumor-targeted immunotherapy

Weijie Cao, Yingmei Li, Jifeng Yu, 2022, Biomarker research.

Clinical implications of recurrent gene mutations in acute myeloid leukemia

Yingmei Li, Jifeng Yu, Zhongxing Jiang, 2020, Experimental Hematology & Oncology.

Clinical Characteristics And Outcome Of Biphenotypic Acute Leukemia: 10 Case Reports And Literature Review

Hui Sun, Yanfang Liu, Chong Wang, 2019, Cancer management and research.

CMAR_A_226058 9297..9306

Hui Sun, Yanfang Liu, Chong Wang, 2019 .

Donor cell leukemia/myelodysplastic syndrome after allogeneic stem cell transplantation: a rare phenomenon with more challenges for hematologists

Weijie Cao, Yingmei Li, Jifeng Yu, 2021, Hematology.

Clinical implications of myeloid malignancy‑related somatic mutations in aplastic anemia

Yingmei Li, Jifeng Yu, Zhongxing Jiang, 2023, Clinical and experimental medicine.

Acute arrest of hemopoiesis presenting as severe aplastic anemia: a retrospective analysis

Yingmei Li, Jifeng Yu, Zhongxing Jiang, 2021, Hematology.

Gene mutational analysis by NGS and its clinical significance in patients with myelodysplastic syndrome and acute myeloid leukemia

Hui Sun, Yanfang Liu, Yingmei Li, 2020, Experimental Hematology & Oncology.

Deficient Regulatory Innate Lymphoid Cells and Differential Expression of miRNAs in Acute Myeloid Leukemia Quantified by Next Generation Sequence

Yingmei Li, Jifeng Yu, Zhongxing Jiang, 2019, Cancer management and research.

Impact of treatments before allogeneic hematopoietic stem cell transplantation in patients with higher-risk myelodysplastic syndrome.

Jifeng Yu, D. Wan, Xinsheng Xie, 2023, Leukemia research.

SIRPα-Fc fusion protein IMM01 exhibits dual anti-tumor activities by targeting CD47/SIRPα signal pathway via blocking the “don’t eat me” signal and activating the “eat me” signal

Yongping Song, D. Liu, Jifeng Yu, 2022, Journal of Hematology & Oncology.

Philadelphia chromosome-positive B-lymphoblastic lymphoma successfully treated with chemotherapy regimen containing imatinib

Weijie Cao, Jifeng Yu, Zhongxing Jiang, 2021, Medicine.

Decreased bone marrow regulatory innate lymphoid cells show a distinctive miRNA profiling in aplastic anemia

F. Wang, Weijie Cao, Yingmei Li, 2020, Hematology.

IMM47, a humanized monoclonal antibody that targets CD24, exhibits exceptional anti-tumor efficacy by blocking the CD24/Siglec-10 interaction and can be used as monotherapy or in combination with anti-PD1 antibodies for cancer immunotherapy

D. Liu, Jifeng Yu, Wenzhi Tian, 2023, Antibody therapeutics.

Targeting CD24/Siglec-10 signal pathway for cancer immunotherapy: recent advances and future directions

Jifeng Yu, Wenzhi Tian, Yongping Song, 2024, Cancer immunology, immunotherapy : CII.

Clinical application value of metagenomic second-generation sequencing technology in hematologic diseases with and without transplantation

Fang Wang, Jifeng Yu, Zhongxing Jiang, 2023, Frontiers in cellular and infection microbiology.

Targeting the CD47/SIRPα pathway in malignancies: recent progress, difficulties and future perspectives

Jifeng Yu, Wenzhi Tian, Zhongxin Jiang, 2024, Frontiers in oncology.

A novel anti-LAG-3/TIGIT bispecific antibody exhibits potent anti-tumor efficacy in mouse models as monotherapy or in combination with PD-1 antibody

Jifeng Yu, Binhua Lv, Ildefonso Vicente‐Suarez, 2024, Scientific reports.

Targeting TIGIT for cancer immunotherapy: recent advances and future directions

Jifeng Yu, Xinyuan Liu, Yongping Song, 2024, Biomarker research.